CliffBio
small molecule

SUMATRIPTAN SUCCINATE

SUMATRIPTAN SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUMATRIPTAN SUCCINATE
Active ingredientSUMATRIPTAN SUCCINATE
StrengthEQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)
Dosage formINJECTABLE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2009
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.